PRNewsWire
21 Feb 2026, 23:05 UTC · 30w ago
Verdict
Headline leans bearish. We score INO −1.00 across four claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
4 claims · scored −1 bearish … +1 bullish
A class action lawsuit alleges Inovio made misleading statements by failing to disclose that manufacturing for its CELLECTRA device was deficient.
More negative than 99% of claims this week
The lawsuit claims Inovio was unlikely to submit the INO-3107 Biologics License Application to the FDA by the second half of 2024 due to the undisclosed deficiencies.
So whatA delayed BLA submission directly pushes back potential revenue generation and damages the company's regulatory timeline, heavily impacting valuation models.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 98% of claims this week
Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, contrary to prior statements.
More negative than 98% of claims this week
As a result of the foregoing disclosures, INO-3107's overall regulatory and commercial prospects were overstated during the class period.
More negative than 98% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities fraud class action lawsuit alleging misleading statements about its CELLECTRA device and BLA submissions.
More negative than 77% of ticker scores this week
The company is the subject of an investigation into potential breaches of fiduciary duties by its directors and officers.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−27.2%
Price agrees with the score
$1.26 vs $1.73 close before publication (Feb 20) · not market-adjusted
INO chart →
